• Value Research Rating market-capitalisation-info
    Not Applicable
  • Market Capitalisation market-capitalisation-info $81 Mln
  • Price to Earnings Ratio price-to-earning --
  • 12 Month Earnings monthly-earning $-31 Mln

Cardiff Oncology Inc. (CRDF) Share Price

$1.77

As on 29-Feb-2024 16:14 EST

up-down-arrow $-0.06-3.02%

  • Prev Close info

    $1.82

  • Day's Openinfo

    $1.91

  • Today's Highinfo

    $1.91

  • Today's Lowinfo

    $1.74

  • Today's Volumeinfo

    206,439

  • 52 Week rangeinfo

    $0.94 - 2.79

Please wait...

Cardiff Oncology Inc. (CRDF) Stock Performance

YTD
1 Month
3 Months
1 Year
3 Years
5 Years
10 Years
Cardiff Oncology (CRDF)
19.26 18.46 41.20 7.62 -44.53 -8.69 -42.93
S&P BSE Sensex*
2.08 2.78 10.09 25.07 14.52 15.51 13.32
S&P Small-Cap 600#
-5.82 -5.34 -13.73 -6.30 5.30 2.98 5.53
As on 29-Feb-2024  |  *As on 01-Mar-2024  |  #As on 26-Oct-2023
2023
2022
2021
2020
2019
2018
2017
Cardiff Oncology (CRDF)
5.71 -76.71 -66.59 1,350.81 -60.67 -85.61 -85.36
S&P Small-Cap 600
13.89 -17.42 25.27 9.57 20.86 -9.70 11.73
S&P BSE Sensex
18.74 4.44 21.99 15.75 14.38 5.87 27.91

Valuation Score

Stock
Peer Median
Please wait...

Growth & Efficiency

Stock
Peer Median
Please wait...

Solvency

Is there a threat to this company's solvency in the future?

Financial Manipulation

Can creative accounting be detected through the financial numbers?

Cardiff Oncology Inc. (CRDF) Peer Comparison

search
search
search
search
    Please wait...

    Valuation Chart of Cardiff Oncology Inc. (CRDF)

      Please wait...
        Please wait...

        Financials

        Please wait...
        Please wait...
        Please wait...

        Shareholding Pattern

        Other details of Cardiff Oncology Inc. (CRDF)

        CEO & Director

        Dr. Mark Erlander Ph.D.

        Chief Financial Officer

        Mr. James E. Levine

        Headquarters

        San Diego, CA

        FAQs for Cardiff Oncology Inc. (CRDF)

        The total asset value of Cardiff Oncology Inc. (CRDF) stood at $ 97 Mln as on 30-Sep-23

        The share price of Cardiff Oncology Inc. (CRDF) is $1.77 (NASDAQ) as of 29-Feb-2024 16:14 EST. Cardiff Oncology Inc. (CRDF) has given a return of -44.53% in the last 3 years.

        Cardiff Oncology Inc. (CRDF) has a market capitalisation of $ 81 Mln as on 29-Feb-2024. As per Value Research classification, it is a Small Cap company.

        The P/B ratio of Cardiff Oncology Inc. (CRDF) is 1.04 times as on 29-Feb-2024, a -0.65% premium to its peers’ median range of 2.98 times.

        Since, TTM earnings of Cardiff Oncology Inc. (CRDF) is negative, P/E ratio is not available.

        Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
        Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
        Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
        Step 4. Search for the Cardiff Oncology Inc. (CRDF) and enter the required number of quantities and click on buy to purchase the shares of Cardiff Oncology Inc. (CRDF).

        Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and hematologic malignancies, such as KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. It primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California. Address: 11055 Flintkote Avenue, San Diego, CA, United States, 92121

        The CEO & director of Dr. Mark Erlander Ph.D.. is Cardiff Oncology Inc. (CRDF), and CFO & Sr. VP is Mr. James E. Levine.

        The promoters of Cardiff Oncology Inc. (CRDF) have pledged 0% of the total equity as on Sep-23.

        Cardiff Oncology Inc. (CRDF) Ratios
        Return on equity(%)
        -45.06
        Return on capital employed(%)
        --
        Debt-to-equity ratio
        0
        Dividend yield(%)
        0

        No, TTM profit after tax of Cardiff Oncology Inc. (CRDF) was $-31 Mln.

        Edit peer-selector-edit
        Please wait...
        Please wait...

        Key Facts

        • Market cap market-cap-information $81.09 Mln
        • Revenue (TTM)revenue-information $0.46 Mln
        • Earnings (TTM) earning-information $-31.09 Mln
        • Cash date-information $81.36 Mln
        • Total Debt info $2.30 Mln
        • Insider's Holding 7.44%
        • Liquidity liquidity High
        • 52 Week range week-range $0.94 - 2.79
        • Shares outstanding share-outstanding 44,677,200
        • 10 Years Aggregate:

          CFO: $-221.95 Mln

          EBITDA: $-220.41 Mln

          Net Profit: $-263.85 Mln

        About The Company

        • IPO Date 27-Jul-2004
        • CEO & Director Dr. Mark Erlander Ph.D.
        • Chief Financial Officer Mr. James E. Levine
        • Listing key-listing NASDAQ: CRDF
        • Country United States
        • Headquarters headquarters San Diego, CA
        • Website website https://www.cardiffoncology.com
        • Business

          Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid...  tumor cancers and hematologic malignancies, such as KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. It primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California. Address: 11055 Flintkote Avenue, San Diego, CA, United States, 92121  Read more

        share-fund-plan-icon